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Abstract
Background: The purpose of the study was to assess the effect of trimetazidine administered
for 20 days in 56 patients with ischemic heart disease treated with maximal tolerated doses of
anti-ischemic drugs who were not candidates for percutaneous or surgical revascularization.
Methods: The efficacy of trimetazidine was evaluated by comparing exercise testing
parameters before and after treatment, combined with the patient response to a questionnaire
administered at baseline and following the treatment. We evaluated the duration of exercise,
workload, double product, time to the occurrence of ischemic changes in ECG, the number of
leads with diagnostic ST segment depression, and the magnitude of ST segment depression.
Results: After 20 days of trimetazidine treatment, an improvement in exercise testing
parameters was seen in about 50% of patients, and the differences of the mean values were
statistically significant. The patient response to the questionnaire administered following the
treatment indicated a decreased frequency of anginal episodes and an increased exercise
duration to the occurrence of angina in two thirds of patients, less requirement for nitrates in
40% of patients, and increased exercise tolerance in 50% of patients. In patients with subjective
response to treatment, comparison of exercise testing parameters before and after treatment
showed significant increase in the duration of exercise, time to ischemic changes in ECG, and
the degree of ST segment depression during peak exercise. In patients with no subjective
response to treatment, a statistically significant difference was seen in the double product only.
Conclusions: After 20 days of treatment with trimetazidine added to maximal anti-ischemic
treatment in patients with refractory angina, an improvement in exercise testing parameters
and subjective response to treatment were seen in about 40% of patients. In patients with
subjective response to treatment, exercise testing parameters improved significantly compared
to the baseline values. (Cardiol J 2008; 15: 344–350)
Key words: stable angina pectoris, metabolic treatment, subjective and objective
evaluation of treatment effects
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Introduction
Percutaneous or surgical revascularization is
the most effective strategy to improve myocardial
perfusion. In some patients, however, neither per-
cutaneous nor surgical revascularization is feasible,
and the drug treatment including beta-blockers,
calcium channel blockers and/or nitrates is not suf-
ficiently effective. An intervention aimed at the
metabolic pathways in ischemic myocardial cells
is a promising therapeutic option in such patients.
With normal myocardial perfusion and optimal oxy-
gen supply, oxidation of fatty acids is the main so-
urce of energy in the heart (60–80%) but also the
most oxygen-consuming process. Regarding other
energy sources in the heart, lactate oxidation is the
source of about 15% of energy used by the myocar-
dium, another 15% comes from glucose oxidation,
and less than 10% comes from anaerobic glycoly-
sis. These proportions change if oxygen supply to
myocardium is limited, with reduced energy pro-
duction through beta-oxidation of fatty acids and
glucose oxidation and limited rate of these proces-
ses. In contrast, anaerobic glycolysis becomes
a major source of energy. Glycolysis and glucose
oxidation become uncoupled, resulting in overpro-
duction of lactate and protons and accumulation of
acylcarnitine and acylcoenzyme A. The latter are
strong detergents disrupting cell membranes and
intracellular enzymatic processes. At the same
time, pain resulting from myocardial ischemia le-
ads to catecholamine release and resulting enhan-
ced lipolysis. Thus, blood free fatty acid levels be-
come elevated, leading to inhibition of glycolysis
and further decrease in glucose oxidation [1–3].
A pharmacologic intervention targeted at the me-
tabolic processes in myocardial cells should impro-
ve effectiveness of energy production, decrease the
oxygen debt, and protect myocardial cells from the
effects of ischemia. These effects are collectively
called cytoprotection. One such cytoprotective drug
is trimetazidine. Cytoprotective drugs are used as
an adjunct to hemodynamic drugs and revasculari-
zation [4, 5].
The purpose of the study was to assess the cli-
nical effectiveness of trimetazidine added to maxi-
mal individually tolerated doses of hemodynamic
anti-ischemic drugs in patients with angina pecto-
ris who were deemed not to be candidates for per-
cutaneous or surgical revascularization. We evalu-
ated the effect of trimetazidine on various exercise
testing parameters and the subjective response to
treatment using a questionnaire regarding quality
of life and exercise tolerance.
Methods
Among our patients who underwent coronary
angiography due to symptomatic ischemic heart
disease (with Canadian Cardiovascular Society
[CCS] class II or III symptoms), we selected 89
patients who were deemed not to be candidates for
percutaneous or surgical revascularization due to
diffuse lesions in the coronary vessels. Exclusion
criteria included inability to perform an exercise
test, anemia, valvular heart disease, and myocar-
dial hypertrophy by echocardiography (defined as
interventricular septum and/or posterior wall thick-
ness > 12 mm). The study was approved by the
Ethics Committee at the Nicolaus Copernicus Uni-
versity Collegium Medicum in Bydgoszcz. After the
patients were informed about the purpose and the
nature of the study and gave written consent for
participation, their existing drug treatment was
optimized. The optimization included adjusting
medications according to the current European
Society of Cardiology guidelines (aspirin, statin,
angiotensin-converting enzyme inhibitor) and incre-
asing doses and/or adding new hemodynamic anti-
ischemic drugs (beta-blockers, calcium channel
blockers, long-acting nitrates). Drug reducing my-
ocardial oxygen requirement were individually ad-
justed depending on specific clinical contraindica-
tions, and the doses used were increased to maxi-
mal individually tolerated ones. Following drug
treatment optimization within 2 to 6 weeks, angi-
nal symptoms became adequately controlled in 33 of
89 originally recruited patients. Thus, the final stu-
dy population included 56 patients with CCS class
II or III symptoms persisting despite adequate
hemodynamic treatment and a positive result of
the exercise testing. The study group consisted of
15 women and 41 men aged 48 to 75 years (mean
age 62.8 years). The participating women were sli-
ghtly older than men (63.8 vs. 62.4 years).
All subject underwent an exercise test twice,
initially after optimization of existing drug treat-
ment, but before trimetazidine administration, and
later after 20 days of treatment with 35 mg of tri-
metazidine (Preductal MR, Servier) given twice
daily. The exercise testing was performed using
a treadmill (Marquette Medical) according to the
Bruce protocol, with 12-lead ECG recorded on
a thermosensitive paper. ST segment deviations
were measured manually. Criteria of termination of
the exercise test included retrosternal chest pain,
ST segment depression by ≥ 0.2 mV, ST segment
elevation by ≥ 0.2 mV, significant ventricular arr-
hythmia (frequent ventricular ectopy, multifocal
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ectopy, ventricular salvoes, non-sustained ventri-
cular tachycardia, sustained ventricular tachycar-
dia, R-on-T ventricular ectopic beats), the occur-
rence of atrial fibrillation and/or flutter, intraven-
tricular or atrioventricular conduction
abnormalities, blood pressure elevation above
220 mm Hg systolic and/or 110 mm Hg diastolic,
no increase or decrease in heart rate during exer-
cise, no increase or decrease in blood pressure du-
ring exercise, and patient request. During the exer-
cise test, the following parameters were evaluated:
resting and maximal exercise-induced heart rate,
resting and maximal exercise-induced systolic and
diastolic blood pressure measured noninvasively,
double product calculated as the maximal exercise-
induced systolic blood pressure multiplied by the
maximal exercise-induced heart rate, total duration
of exercise, exercise duration to diagnostic ST seg-
ment depression, peak workload measured in meta-
bolic equivalents (METs), the magnitude of ST seg-
ment depression in 12-lead ECG, and the number of
leads with diagnostic ST segment depression.
Subjective evaluation of the quality of life and
exercise tolerance was based on the response to
a questionnaire administered at baseline and after
20 days of treatment with trimetazidine. In the qu-
estionnaire, patients were asked about the frequ-
ency of anginal episodes, exercise distance to the
occurrence of angina, the number of flights of sta-
irs climbed without anginal pain, the frequency of
short-acting nitrate use, and whether they saw im-
provement, no change, or worsening of exercise
tolerance and quality of life upon treatment.
Statistical analysis of the data included Student
t test to compare mean values of normally distribu-
ted variables. P value of less than 0.05 was conside-
red statistically significant. Wilcoxon test was used
to compare dependent samples. Two-fraction test
was used to compare proportions of response and no
response to treatment as measured using pre- and
post-treatment exercise test. Mann-Whitney test
was used to compare distributions of samples.
Results
Our results regarding exercise test parameters
are presented in Table 1. Total duration of the exer-
cise test after 20 days of trimetazidine treatment
increased in 69.6% of patients, did not change in
1.8% of patients, and decreased in 28.6% of patients.
Mean total duration of the exercise test increased
by 21.6 s (from 322.7 s to 344.3 s), and this diffe-
rence was statistically significant (p < 0.003). Du-
ration of the exercise test to the occurrence of dia-
gnostic ST segment changes after 20 days of trime-
tazidine treatment increased in 46.4% of patients,
did not change in 28.6% of patients, and decreased
in 25% of patients. Mean duration of exercise to the
occurrence of diagnostic ST segment changes was
226.4 s at baseline and increased to 275.9 s after
20 days of trimetazidine treatment. The difference
of 49.5 s was statistically significant (p < 0.0002).
Workload after 20 days of trimetazidine treatment
compared to baseline increased in 41.1% of patients,
did not change in 39.3% of patients, and decre-
ased in 19.6% of patients. Mean workload before
trimetazidine treatment was 6.5 METs, compared
to 6.8 METs after trimetazidine treatment. The diffe-
rence of 0.3 MET was statistically significant (p < 0.03).
ST segment changes were measured manually in
12-lead ECG. Overall, we analyzed 672 leads at ba-
seline and after 20 days of trimetazidine treatment.
Of these, 235 leads showed changes compared to
baseline. The number of leads with diagnostic ST
segment changes decreased in 46.4% of patients,
did not change in 41% of patients, and increased
in 9.1% of patients. The degree of ST segment de-
pression decreased in 51.1% of leads, did not chan-
ge in 28.5% of leads, and increased in 20.4% of
leads. Double product calculated as the maximal
Table 1. Exercise test parameters before and after 20 days of trimetazidine treatment.
Exercise test Mean Mean values after Difference P
parameter pretreatment  20 days of trimetazidine
values treatment
Total duration of exercise [s] 322.7 344.3 21.6 < 0.003
Duration of exercise to the occurrence 226.4 275.9 49.5 < 0.0002
of diagnostic ST segment depression [s]
Peak workload [METs] 6.5 6.8 0.3 < 0.03
Double product 19,051 17,630 1421 < 0.02
ST segment deviation [mm] –1.58 –1.29 0.29 < 0.0001
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exercise-induced systolic blood pressure multiplied
by the maximal exercise-induced heart rate, reflec-
ting adaptation of the cardiovascular system to
exercise, decreased after 20 days of trimetazidine
treatment. The mean value of the double product
decreased from 19,051 to 17,630, and this differen-
ce was statistically significant (p < 0.02).
The exercise test parameters were compared
between men and women, hypertensive and normo-
tensives, and patients with and without diabetes.
We found no significant differences in these para-
meters between both genders and between patients
with and without diabetes, although a trend was
seen towards more improvement of the exercise
test parameters in patients with diabetes compared
to patients without diabetes (Table 2). Among hy-
pertensives, we found significantly higher number
of ECG leads with decreased ischemic changes and
lower number of ECG leads with diagnostic ST seg-
ment changes compared to normotensives.
Table 3 shows results of subjective evaluation
of the effects of trimetazidine treatment. A qu-
estionnaire administered before and after 20 days
of trimetazidine treatment included questions re-
garding the frequency of anginal episodes, exerci-
se distance to the occurrence of angina, require-
ment for short-acting nitrates, and a subjective fe-
eling of improvement.
Subjective improvement was reported by
71.4% of patients (n = 40). Overall, 66% of patients
reported a decreased frequency of anginal episodes,
32% of patients reported no change in the frequen-
cy of anginal episodes, and one patient reported an
increased frequency of anginal episodes following
trimetazidine treatment. In addition, 60.7% of pa-
tients reported an increased exercise distance to the
occurrence of angina, 32.1% of patients reported no
change of the exercise distance to the occurrence
of angina, and 7.1% of patients reported a decreased
distance to the occurrence of angina. The require-
ment for nitrates following trimetazidine treatment
decreased in 42.8% of patients, did not change in
53.6% of patients, and increased in two patients
(3.6%). Subjectively reported exercise tolerance,
expressed as the number of flights of stairs that
could be climbed without anginal pain, increased in
51.8% of patients and did not change in 46.4% of
patients. One patient reported that the exercise
tolerance was worse following trimetazidine treat-
ment compared to baseline.
Next, we compared the mean values of exercise test
parameters between patients with subjective improve-
Table 2. Comparison of the mean values exercise test parameters between patients with diabetes
(n = 14) and patients without diabetes (n = 42).
Exercise test parameter Patients with diabetes Patients without diabetes Test
n Mean SD n Mean SD t-Student p
Mean increase in the total 14 –0.27 48.0 42 29.2 55.1 –1.74 NS
duration of exercise [s]
Mean increase in the duration 14 28.0 78.7 42 55.3 96.9 –0.88 NS
of exercise to the occurrence
of ST segment changes [s]
Mean increase 14 0.87 3.76 42 0.40 1.15 0.70 NS
in the peak workload [METs]
Mean decrease in 14 –1818 4465 42 –1245 4057 –0.44 NS
the double product
Mean change of the ST 14 –0.28 0.82 42 –0.30 0.77 0.17 NS
segment depression [mm]
Table 3. Subjective evaluation of the effects of
trimetazidine treatment.
Parameter Reported Number of
effect patients (%)
Frequency Lower 37 (66.1)
of anginal pain No change 18 (32.1)
Increased 1 (1.8)
Exercise distance Longer 34 (60.7)
to the occurrence No change 18 (32.1)
of angina Shorter 4 (7.1)
Short-acting Lower 24 (42.8)
nitrate use No change 30 (53.6)
Higher 2 (3.6)
Exercise tolerance Better 29 (51.8)
No change 26 (46.4)
Worse 1 (1.8)
Subjective Yes 40 (71.4)
improvement No 16 (28.6)
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ment following trimetazidine treatment (40 patients) and
no such improvement (16 patients). We found no signi-
ficant differences in any of the exercise test parameters
between these two groups of patients (Table 4).
Among 40 patients reporting subjective improve-
ment following trimetazidine treatment, we found an
improvement during the exercise test regarding any of
the parameters evaluated (total duration of the exercise
test, duration of the exercise test to the occurrence of
pain or ST segment changes, peak workload, magnitu-
de of ST segment depression) in 22 of them (39.3% of
all patients). We found no objective improvement in the
remaining 18 (32.1%) patients who reported subjective
improvement following trimetazidine treatment.
Among 16 patients reporting no subjective im-
provement following trimetazidine treatment, we fo-
und no improvement in the evaluated parameters of
the exercise test in 11 (19.6%) of them, and in 5 of
these patients (8.9%) parameters of the exercise test
improved following trimetazidine treatment.
In patients with subjective response to treat-
ment, comparison of exercise testing parameters be-
fore and after treatment showed significant increase
in the duration of exercise, time to ischemic changes
in ECG, and the degree of ST segment depression.
In patients with no subjective response to treatment,
a statistically significant difference was seen only in
the mean value of the double product (Table 5).
Table 4. Comparison of the mean values exercise test parameters between patients with subjective
improvement and patients without subjective improvement.
Parametr Patients with Patients without p
subjective improvement subjective improvement
n Mean SD n Mean SD
Mean increase in the total 40 27.8 62.3 16 8.2 32.8 NS
duration of exercise [s]
Mean increase in the duration 40 54.3 100.0 16 38.0 78.3 NS
of exercise to the occurrence
of ECG changes [s]
Mean increase in the peak 40 0.34 1.30 16 0.17 0.62 NS
workload [METs]
Mean decrease 40 –1135 4300 16 –2023 3924 NS
in the double product
Mean change of the ST 162 –0.35 0.78 73 –0.16 0.78 NS
segment depression [mm]
Table 5. Comparison of the exercise test parameters at baseline and after 20 days of trimetazidine
treatment between patients with subjective improvement following trimetazidine treatment and
patients without subjective improvement following treatment.
Parameter Patients with Test Patients without Test
subjective improvement subjective improvement
n Mean SD t-Student p n Mean SD t-Student p
Mean increase in the total 40 27.8 62.3 2.71 0.01 16 8.2 32.8 1.03 NS
duration of exercise [s]
Mean increase in the duration 40 54.3 100.0 3.30 < 0.003 16 38.0 78.3 1.88 NS
of exercise to the occurrence
of ECG changes [s]
Mean increase in the peak 40 0.34 1.30 1.59 NS 16 0.17 0.62 1.13 NS
workload [METs]
Mean decrease 40 –1135 4300 –1.60 NS 16 –2023 3924 –2.12 0.05
in the double product
Mean change of the ST 162 –0.35 0.78 –5.69 < 0.0001 73 –0.16 0.78 –1.74 NS
segment depression [mm]
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Discussion
Patients with ischemic heart disease who are
not candidates to revascularization that cannot be
adequately controlled in terms of anginal pain using
optimal drug treatment (with maximal individually
tolerated doses of drugs decreasing myocardial oxy-
gen requirement) are a special group of patients.
Indeed, cytoprotective therapy is most commonly
used in such patients in clinical practice. This is
a heterogeneous group of patients in terms of the
metabolic state of the myocardium, with different
size of the hibernated myocardium and different
degree of the collateral circulation. Thus, the effects
of metabolic treatment may vary in such a popula-
tion. The effectiveness of trimetazidine added to
standard anti-ischemic treatment has been confir-
med in many studies [6–8]. In our study, we evalu-
ated the effectiveness of 20-day treatment with tri-
metazidine added to maximal individually adjusted
anti-ischemic regimen. We used both objective
(exercise test parameters) and subjective (qu-
estionnaire) measures to evaluate the effect of tre-
atment, comparing results of both evaluations.
Comparison of the exercise test parameters before
and after 20 days of trimetazidine treatment reve-
aled that all evaluated parameters (total exercise
duration, peak workload, duration of the exercise
to the occurrence of diagnostic ST segment chan-
ges, severity of the ischemic changes, and the num-
ber of ECG leads showing signs of myocardial ische-
mia) improved following trimetazidine treatment in
about 50% of patients, and the differences were sta-
tistically significant. Many studies showed the ef-
fectiveness of trimetazidine treatment compared to
placebo [9, 10]. In our study, we tried to verify
subjective evaluation of the effects of trimetazidi-
ne treatment in an objective way, comparing exer-
cise test parameters between patients with subjec-
tive improvement or no subjective improvement
following treatment. Among patients who reported
improvement (71.4% of the study population), two
subsequent exercise tests differed significantly in
regard to total duration of exercise, duration of exer-
cise to the occurrence of diagnostic ECG changes,
and the magnitude of ST segment depression, with
better results following 20-day trimetazidine treat-
ment. Among patients who reported no subjective
improvement (28.6%) of the study population),
a statistically significant difference was seen in the
double product only. Decreased value of the double
product was most commonly the effect of lower
maximal exercise-induced heart rate, indirectly
suggesting better exercise tolerance despite no
such improvement being reported by the patient.
Improvement of quality of life and left ventricular
function following trimetazidine treatment were
also reported by other authors [11].
Another interesting finding was a significantly
higher reduction of in the number of ECG leads with
diagnostic ST segment changes during exercise test
following 20-day trimetazidine treatment in patients
with hypertension (by 58%) compared to patients
without hypertension (by 33%; p < 0.001). In these
patients, the mean change of ST segment depression
following trimetazidine treatment was –0.76 mm com-
pared to +0.786 mm in patients without hypertension
(p < 0.02). Exercise-induced ST segment depression
diagnostic for myocardial ischemia that occurs wi-
thout significant lesions in the coronary arteries is a
common finding in patients with hypertension. This
may by explained by myocardial hypertrophy and
inadequate perfusion of increased myocardial mu-
scle mass, or small vessel disease (endothelial dys-
function). However, patients with left ventricular
hypertrophy were not included in the present stu-
dy. Can trimetazidine treatment lead to improved
endothelial function? There are only few data on this
issue in the literature but one study showed decre-
ased endothelin release by endothelial cells follo-
wing trimetazidine treatment [12].
Diabetes leads to changes in the myocardial cell
metabolism, as well as disturbed ion transport. Ani-
mal studies showed impaired glucose transport to car-
diomyocytes. This favors anaerobic glycolysis, resul-
ting in lactate accumulation and lactic acidosis. This
in turn delays cardiomyocyte function recovery follo-
wing an ischemic episode, decreasing the likelihood
that affected heart cells will survive. In addition, glu-
cose and lactate oxidation rate is reduced in patients
with diabetes due to impaired ability of mitochondria
to oxidize pyruvate, resulting from increased acetyl-
coenzyme A and free fatty acid levels. Concomitant
impairment of calcium transport also contributes to de-
creased myocardial contractility [13]. Patients with
diabetes comprised 25% of our study population. In
these patients, we found a trend towards improvement
of exercise test parameters compared to patients wi-
thout diabetes that did not reach statistical significan-
ce. Similar results were obtained in TRIMPOL I study
and in the study by Ribeiro et al. [14]. Fragasso et
al. [15] found improved glucose metabolism parame-
ters (increased total tissue glucose disposal, lower
blood fasting glucose level, improvement in insulin
sensitivity) in patients with diabetes treated with tri-
metazidine. Perhaps the duration of trimetazidine tre-
atment in our study was too short to show statistical
significance of the observed differences.
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We found concordant subjective and objective
improvement in 39.3% of patients treated with tri-
metazidine. In addition, objective but not subjecti-
ve improvement was seen in 8.9% of patients. Thus,
overall 48.2% of the studied patients benefited from
trimetazidine treatment.
Limitations of our study included short dura-
tion of follow-up (although many studies showed
early benefits of trimetazidine treatment), no pla-
cebo control group or crossover placebo control, and
the specific way questions in the questionnaire re-
garding subjective effects of trimetazidine treat-
ment were constructed. The responding patients
did not give quantitative data on short-acting nitra-
te use but only compared current and previous ni-
trate use which may lack adequate precision.
Conclusions
1. In approximately 40% of patients with ische-
mic heart disease who are not candidates to
myocardial revascularization, 20-day trimeta-
zidine treatment improved both exercise test
parameters and subjective symptoms related
to myocardial ischemia.
2. In patients with subjective improvement follo-
wing trimetazidine treatment, exercise test pa-
rameters improved significantly compared to
the pretreatment values.
3. Short duration of trimetazidine treatment and
probably also some “metabolic heterogeneity”
of the studied population may explain lack of
benefits of trimetazidine treatment in some
patients.
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